Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,887 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge.
Kim HY, Choi JH, Haque MM, Park JH, Kim IH, Choi BK, Lee A, Park S. Kim HY, et al. Among authors: kim ih. Cancer Immunol Immunother. 2022 Apr;71(4):967-978. doi: 10.1007/s00262-021-03120-1. Epub 2022 Jan 6. Cancer Immunol Immunother. 2022. PMID: 34988585 Free PMC article.
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, Kang BW, Ryu H, Lee JS, Kim KW, Abou-Alfa GK, Ryoo BY. Yoo C, et al. Lancet Oncol. 2021 Nov;22(11):1560-1572. doi: 10.1016/S1470-2045(21)00486-1. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656226 Clinical Trial.
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, Kim IH, Lee YG, Shin SH, Park SE, Jung J, Kang EJ, Ahn MJ. Kim H, et al. Among authors: kim ih, kim dw, kim m. Cancer. 2022 Feb 15;128(4):778-787. doi: 10.1002/cncr.33984. Epub 2021 Oct 27. Cancer. 2022. PMID: 34705268 Free PMC article.
1,887 results